Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Specific driver mutations in lung adenocarcinoma (LUAD) alter the tumor microenvironment (TME). Co-mutations in KRAS/EGFR with TP53 reshape the TME, potentially driving resistance to tyrosine kinase inhibitors (TKIs).
Area Of Science
- Oncology
- Molecular Biology
- Cancer Genomics
Background
- Lung adenocarcinoma (LUAD) exhibits molecular diversity driven by specific mutations.
- The tumor microenvironment (TME) significantly influences LUAD progression and treatment response.
- Understanding the interplay between LUAD drivers and the TME is critical for therapeutic advancement.
Purpose Of The Study
- To investigate how driver mutations impact the composition and spatial organization of the TME in LUAD.
- To correlate specific LUAD driver mutations with TME characteristics and patient outcomes.
- To explore the role of co-mutations in shaping TME-mediated therapeutic resistance.
Main Methods
- Imaging mass cytometry (IMC) was employed to analyze the TME in 157 LUAD patient samples.
- Genomic and clinical data were integrated with IMC data for comprehensive analysis.
- Spatial architecture and cellular composition of the TME were assessed in relation to driver mutations.
Main Results
- Distinct TME patterns were identified in LUAD tumors based on specific driver mutations.
- Mutated KRAS and EGFR tumors with TP53 co-mutations exhibited unique TME compositions and architectures.
- These co-mutations are suggested to contribute to resistance against tyrosine kinase inhibitors (TKIs).
Conclusions
- Oncogenic driver mutations profoundly influence the TME in LUAD.
- Co-mutations, particularly involving TP53, significantly reshape the LUAD TME.
- Integrating genomic and cellular data is essential for understanding LUAD tumor biology and predicting prognosis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...